炭疽毒素受体与人IgG1的Fc段融合蛋白ATR_Fc在CHO细胞中的表达

ATR_Fc是人炭疽毒素受体(ATR)的胞外区与人免疫球蛋白IgG1的铰链区、CH2区和CH3区组成的融合蛋白。表达该蛋白是为了获得结合PA的抗体样分子,通过阻断PA与细胞受体的结合,而阻止炭疽致死毒素和水肿因子进入细胞内,可作为预防和治疗炭疽感染的生物制品。将编码炭疽毒素受体N端1_227氨基酸的基因和编码Fc段的基因连接,插入到pcDNA3.1的HindⅢ和NotⅠ位点得到表达ATR_Fc融合蛋白的真核表达载体pcDNA3.1ATR_Fc,并用脂质体方法将该载体转染至CHO_K1细胞中,用G418筛选并获得ATR_Fc表达水平为10～15μg(106cells·d)的基因工程CHO细胞系ATR_Fc_1D5。采用蛋白A纯化重组蛋白,并用ELISA法鉴定ATR_Fc与PA的亲和性,表明ATR_Fc可与PA特异性结合。     

炭疽毒素受体与人IgG1的Fc段融合蛋白ATR_Fc在CHO细胞中的表达

ATR-Fc是人炭疽毒素受体（ATR）的胞外区与人免疫球蛋白IgG1的铰链区、CH2区和CH3区组成的融合蛋白。表达该蛋白是为了获得结合PA的抗体样分子,通过阻断PA与细胞受体的结合,而阻止炭疽致死毒素和水肿因子进入细胞内,可作为预防和治疗炭疽感染的生物制品。将编码炭疽毒素受体N端1-227氨基酸的基因和编码Fc段的基因连接,插入到pcDNA3-1的HindⅢ和NotⅠ位点得到表达ATR-Fc融合蛋白的真核表达载体pcDNA31/ATR9Fc,并用脂质体方法将该载体转染至CHO-K1细胞中,用G418筛选并获得ATR-Fc表达水平为10～15μg/(106cells·d)的基因工程CHO细胞系ATR-Fc-1D5。采用蛋白A纯化重组蛋白,并用ELISA法鉴定ATR-Fc与PA的亲和性,表明ATR-Fc可与PA特异性结合。     

人GLP -1- IgG Fc融合蛋白在毕赤酵母中的高效表达

目的:构建GLP-1-IgG Fc融合蛋白分子并在毕赤酵母中实现高效表达.方法:使用蛋白质工程技术改造GLP -1,去除其蛋白酶降解位点,然后利用重叠延伸PCR方法得到改造后的GLP -1与人IgG-Fc片断的嵌合体基因并将其插入pPIC9K载体中.以重组载体转化巴斯德毕赤酵母菌中进行表达.采用SDS-PAGE和Western Blot方法检测重组蛋白的表达.结果:成功的构建了GLP -1-IgG Fc嵌合体基因并使其在重组毕赤酵母中高效分泌表达.在25℃条件下,摇瓶培养添加0.5％甲醇诱导72h后融合蛋白的表达量最大,为5mg/L.SDS-PAGE和Westem-Blot结果表明表达产物为GLP -1-IgG Fc融合蛋白.结论:获得了高效表达GLP -1-IgG Fc融合蛋白的毕赤酵母菌株,为GLP -1-IgG Fc的活性和半衰期测定及下一步的开发奠定了基础,并为在毕赤酵母菌中表达其他Fc融合蛋白和抗体提供了参考.     

重组BPI23—Fcγ1融合蛋白在CHO细胞中的表达

The fusion gene of BPI23 and human Fc gamma 1 was obtained by PCR method, and the expression plasmid was constructed to express recombinant BPI23-Fc gamma 1 fusion protein in CHO cells. After transfection with the plasmid and selection by methotrexate, the cell lines expressing the fusion protein were obtained. The recombinant protein was purified using cation-exchange chromatography and its bioactivity was proved with bactericidal assays.     

Fc 融合蛋白在药学领域的研究进展

Fc 融合蛋白是指利用基因工程等技术将某种具有生物活性的功能蛋白分子与Fc 片段融合而产生的新型重组蛋白,其不仅保留了功能蛋白分子的生物学活性,还具有一些抗体的性质,如通过结合相关Fc 受体延长半衰期和引发抗体依赖细胞介导的细胞毒性效应等。对Fc融合蛋白及其在药学领域的研究进展进行了综述。     

TPO模拟肽与人IgG1Fc融合蛋白在毕赤酵母中的表达及活性鉴定

构建TPO模拟肽与人IgG1Fc融合蛋白的酵母表达体系。利用PCR技术,从重组质粒pET28a-TMPFc中,扩增TPO模拟肽与人IgG1Fc 的DNA片段,连入pPICZαA酵母表达载体,电激法转化毕赤酵母。用MDH和MMH筛选具有正确表型的重组转化子,PCR、蛋白质印迹鉴定融合基因。MTT法鉴定TMPFc对Ba/F3mpl细胞生长的促进作用。构建的重组毕赤酵母实现了TMPFc的分泌表达,表达量占外分泌蛋白质的65%。表达蛋白质的相对分子量约64kD,对Ba/F3mpl生长具有促进作用。TMPFc酵母表达体系表达出可观的二价模拟肽,为二价TMP活性的定量研究奠定基础。     

计算机辅助设计可溶性BLyS受体, eBCMA-Fc 融合蛋白及其在大肠杆菌中的表达

B 细胞成熟抗原 (BCMA)是 B淋巴细胞刺激因子(BLyS)的受体之一．它的胞外区与人IgG1 Fc的融合蛋白eBCMA-Fc,又称为诱饵受体,具有拮抗BLyS的活性．为了设计新的拮抗肽,基于BCMA和Fc的晶体结构,通过计算机图形学技术、分子模拟方法,建立了eBCMA-Fc融合蛋白的三维理论结构．利用均方根位移（root mean square distance, RMSD）对eBCMA-Fc融合蛋白与单体eBCMA、Fc构象差异进行分析．融合蛋白eBCMA-Fc中的eBCMA段与单体eBCMA的主链碳原子间RMSD值为0.036 nm,Fc段与单体Fc的主链碳原子间RMSD值为0.064 nm．结果表明,对比单体,融合蛋白eBCMA-Fc并未因eBCMA与Fc直接连接而发生构象的变化．分子对接方法显示,融合蛋白eBCMA-Fc中的BCMA与BLyS作用,而Fc扮演着稳定BCMA构象的支架作用．为进一步验证上述理论分析,构建eBCMA-Fc融合基因,并将载有eBCMA-Fc融合基因的原核表达质粒转化BL21 (DE3)菌、在细菌中表达．目的蛋白经蛋白A亲和柱纯化大约为36 kD,与理论预测值34 kD相近．免疫印迹表明抗人IgG抗体能够识别eBCMA-Fc融合蛋白．ELISA证实,eBCMA-Fc融合蛋白能够结合BLyS．随着eBCMA-Fc融合蛋白增加,结合BLyS的融合蛋白也相应增加．而对照人IgG,即使在高浓度条件下,也不结合BLyS．此外,eBCMA-Fc 融合蛋白能够抑制BLyS对B细胞肿瘤Daudi细胞的作用．这些研究为下一步设计和筛选BLyS拮抗肽提供了实验基础．     

人肿瘤坏死因子可溶性受体Ⅰ与人IgG∶Fc的融合基因的构建及其在大肠杆菌中的表达

采用PCR方法引入编码氨基酸残基序列为GGGGSGGGGS的接头,将sTNFR1 cDNA与人IgG:Fc cDNA片段连接,构成融合基因fusion 1。将fusion 1克隆在pBSⅡ SK+载体上。测定序列后,转入pRSET-B表达载体,在大肠杆菌中表达,得到分子量 为45kDa的蛋白,超声破碎后电泳证明表达的蛋白为包涵体,经免疫蛋白印迹证实为我们构建的融合蛋白。     

人IL35-IgG4(Fc)融合蛋白在CHO/DG44细胞中的稳定表达

本研究利用基因重组技术构建人IL35-IgG4(Fc)融合基因真核表达载体, 稳定转染CHO/DG44细胞并检测重组蛋白的表达。主要采用聚合酶链式反应(PCR)从脂多糖(Lipopolysaccharides, LPS)诱导的人髓性白血病细胞株KG-I cDNA文库中克隆EBI3和IL-12p35 cDNA, 重叠PCR法连接2个片段, 并克隆到IgG4(Fc)- pOptiVEC?-TOPO?载体上,对新构建的IL-35-IgG4 (Fc) pOptiVEC?-TOPO?真核表达载体并进行酶切、测序、PCR鉴定; 脂质体法转染CHO/DG44细胞; RT-PCR检测转染结果, 采用a-MEM-培养基筛选实验组细胞, 对筛选的阳性克隆细胞再进行氨甲喋呤(Methotrexate, MTX)的加压筛选, ProteinG-Agarose纯化阳性克隆培养上清, 免疫印迹检测目的蛋白表达。结果显示IL-35-IgG4 (Fc) pOptiVEC?-TOPO?表达载体稳定转染CHO/DG44细胞并获得阳性克隆; SDS-PAGE电泳得到一条与预期相对分子质量大小相符的蛋白条带; 该蛋白能与羊抗人IgG4抗体特异结合。本实验获得了能够稳定表达具有稳定结构的IL35-IgG4(Fc)融合蛋白的CHO/DG44细胞株。     

TPO模拟肽与人IgG1 Fc片段的融合表达及其生物学特性研究

依据本室获得的人TPO模拟肽序列,合成了该模拟肽的DNA序列,分别连接至4种不同长度的人IgG1 Fc基因片段的5′端,并克隆至质粒表达载体pET28a( ),转化大肠杆菌BL21（DE3）,筛选获得了4种重组工程菌,其中3种分别高效表达了3种不同长度的融合蛋白,而第4种工程菌未表达,表达的3种融合蛋白的分子量分别约为28kD,12kD和12kD。表达量约占菌体蛋白总量的30％左右,纯化获得了3种TPO模拟肽融合蛋白,3种融合蛋白均有较好的体外活性,维持TPO依赖细胞Ba/F3-mp1生长的EC50分别为：13,10,10nmol/L,用血小板减少症小鼠动物模型,测定了它们的体内活性,3种融合蛋白均有升高血小板和缩短血小板恢复时间的功能,分别比TPO模拟肽活性提高了18,8,8倍,而对白细胞及红细胞无显著影响,分别用3种融合蛋白免疫BALB／c小鼠,均未刺激小鼠产生抗TPO模拟肽抗体,并显示了较好的应用潜力。     

Pharmacokinetic properties of IgG and various Fc fusion proteins in mice

Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative study of different antibody-derived Fc fusion proteins. We could confirm that fusion of single-chain Fv (scFv) and single-chain diabody (scDb) molecules to an Fc region yields in fusion proteins with substantially extended half-lives compared with the single-chain versions. However, even fusion proteins with a size similar to that of IgG, e.g., scDb-Fc, did not have a half-life as long as an IgG molecule. Binding to the neonatal Fc receptor (FcRn) under acidic and neutral conditions was similar for IgG and all Fc fusion proteins. However, we observed differences between IgG and the Fc fusion proteins for dissociation of FcRn-bound proteins induced by shifting from acidic to neutral pH, reflecting the physiological release mechanism, further supporting a contribution of the kinetics of pH-dependent release from FcRn to the pharmacokinetic properties of IgG and Fc fusion proteins.     

hsRAGE-IgG Fc融合蛋白的表达及其生物学活性

将编码人可溶性晚期糖基化终产物受体-免疫球蛋白G Fc段(hsRAGE-IgG Fc)融合蛋白的DNA片段克隆到大肠杆菌表达载体pET-20b中,构建重组表达质粒,转化大肠杆菌Rosetta(DE3)并表达。SDS-PAGE分析表明其表达形式为包涵体,相对分子质量约为66kDa,表达量占菌体总蛋白的38.4%。经复性后,获得纯度为96.6%的融合蛋白,得率约为29.5mg/L。经Western印迹法鉴定,该融合蛋白可与sRAGE抗体产生阳性反应。同时,hsRAGE-IgG Fc融合蛋白可以显著抑制晚期糖基化终产物(AGE)引起的ECV-304细胞NF-κB p65表达的上调,其活性与hsRAGE相似。     

TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties

BAFF is a B cell survival factor that binds to three receptors BAFF-R, TACI and BCMA. BAFF-R is the receptor triggering na?ve B cell survival and maturation while BCMA supports the survival of plasma cells in the bone marrow. Excessive BAFF production leads to autoimmunity, presumably as the consequence of inappropriate survival of self-reactive B cells. The function of TACI has been more elusive with TACI(-/-) mice revealing two sides of this receptor, a positive one driving T cell-independent immune responses and a negative one down-regulating B cell activation and expansion. Recent work has revealed that the regulation of TACI expression is intimately linked to the activation of innate receptors on B cells and that TACI signalling in response to multimeric BAFF and APRIL provides positive signals to plasmablasts. How TACI negatively regulates B cells remains elusive but may involve an indirect control of BAFF levels. The discovery of TACI mutations associated with common variable immunodeficiency (CVID) in humans not only reinforces its important role for humoral responses but also suggests a more complex role than first anticipated from knockout animals. TACI is emerging as an unusual TNF receptor-like molecule with a sophisticated mode of action.     

Vsig4 和免疫球蛋白Fc段融合蛋白的真核表达纯化

目的:本项目将通过构建中国仓鼠卵巢细胞(Chinese hamster ovary,CHO)真核表达系统获取小鼠Vsig4膜外端和免疫球蛋白Ig G3a-Fc段的融合蛋白,鉴定Vsig4-Fc和Vsig4纳米抗体的相互作用。方法:采用重合延伸PCR法融合小鼠Ig G3a-Fc和Vsig4胞外段的基因序列,将该融合基因插入真核表达载体中并转染CHO细胞。Western blotting鉴定转染细胞上清中的目标蛋白,通过连续两次亚克隆筛选,获得高表达小鼠Vsig4-Fc融合蛋白的单克隆,之后大量培养增殖转染细胞并收集细胞培养上清,选择Protein A柱纯化方法纯化Vsig4-Fc蛋白,最后经ELISA法鉴定Vsig4-Fc和纳米抗体的结合能力。结果:在CHO细胞中成功构建了小鼠Vsig4-Fc真核表达稳转系,并且在真核表达体系中获得可表达15 mg/L的双分子结构Vsig4-Fc的稳定转染细胞系。经鉴定小鼠Vsig4-Fc融合蛋白能与Vsig4纳米抗体结合。结论:重合延伸PCR法使得Vsig4和Fc基因片段的融合更为高效,两次亚克隆筛选优势细胞系大幅提高了真核蛋白的表达量,为进一步研究Vsig4的生物学功能奠定重要基础。     

Expression of a novel recombinant stem cell factor/macrophage colony-stimulating factor fusion protein in baculovirus-infected insect cells

A novel human stem cell factor (SCF)/macrophage colony-stimulating factor (M-CSF) fusion protein gene was constructed, in which the coding regions of human SCF cDNA (1-165aa) and the truncated M-CSF cDNA (1-149aa) were connected by a linker sequence encoding a short peptide GGGGSGGGGSGG. The SCF/M-CSF gene was cloned into baculovirus transfer vector pVL1392 under the control of polyhedrin promoter and expressed in the Sf9 cells (Spodoptera frugiperda). SDS-PAGE and Western blot analysis showed that the purified fusion protein was a homodimer with a molecular weight about 84kDa under non-reducing conditions or a monomer about 42kDa under reducing conditions. The specific activity of rhSCF/M-CSF was 17 times as high as that of monomeric rhSCF to stimulate the proliferation of TF-1 cell. The results of macrophages colony-forming (CFU-M) assay performed with human bone marrow mononuclear cells demonstrated that rhSCF/M-CSF was more potent in promoting CFU-M than the equimolar of SCF, M-CSF or that of two cytokines mixture.     

鸡传染性支气管炎病毒S1基因与猪IgG Fc基因在HeLa细胞中的融合表达

根据Genbank中发表的猪IgG Fc段基因及IBV S1基因序列,设计并合成引物。以猪肝组织总RNA为模扩增出猪IgG Fc基因,以含全长IBV M41 S基因的质粒为模板扩增出IBV S1基因,分别克隆至T载体。DNA测序表明,所获得的IBV S1基因大小为1.5 kb,IgG Fc大小为1kb,序列正确。将IBV S1与IgG Fc基因串连,插入含有人组织型纤维蛋白溶酶原激活物分泌信号肽序列(tPA)真核表达载体pcDNA3.1-tPA上,在HeLa细胞上进行瞬时融合表达。经免疫荧光和斑点杂交检测,表达产物同时具有IBV S1蛋白和IgG Fc活性。     

Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells

The presence of aggregated forms of proteins can be problematic for therapeutics due to the potential for immunogenic and pharmacokinetic issues. Although downstream processing can remove the aggregated forms, inhibiting aggregate formation upstream during the cell culture stage could reduce the burden on downstream processing and potentially improve process yields. This study first examined the effects of environmental factors (temperature, pH, and dissolved oxygen) and medium components (bivalent copper ion, cysteine, and cystine) on the aggregation of two different recombinant fusion proteins expressed by Chinese hamster ovary (CHO) cells. Any strategy to reduce protein aggregation upstream during cell culture must also consider potential effects on critical upstream parameters such as cell growth, harvest titer, and protein sialylation levels. Manipulating the culture temperature shift and cystine concentration in the medium were both identified as effective and practical strategies for reducing protein aggregation in both CHO-cell expression systems. Furthermore, a combination of both strategies was more effective in reducing protein aggregation levels compared to either approach individually; and without any negative effects on harvest titer and protein sialylation. This study demonstrates a practical methodology for decreasing protein aggregation during upstream processing and emphasizes the importance of process understanding to ensure production of recombinant glycoprotein therapeutics with consistent product quality.     

Expression and subcellular targeting of canine parvovirus capsid proteins in baculovirus-transduced NLFK cells

A mammalian baculovirus delivery system was developed to study targeting in Norden Laboratories feline kidney (NLFK) cells of the capsid proteins of canine parvovirus (CPV), VP1 and VP2, or corresponding counterparts fused to EGFP. VP1 and VP2, when expressed alone, both had equal nuclear and cytoplasmic distribution. However, assembled form of VP2 had a predominantly cytoplasmic localization. When VP1 and VP2 were simultaneously present in cells, their nuclear localization increased. Thus, confocal immunofluorescence analysis of cells transduced with the different baculovirus constructs or combinations thereof in the absence or presence of infecting CPV revealed that the VP1 protein is a prerequisite for efficient targeting of VP2 to the nucleus. The baculovirus vectors were functional and the genes of interest efficiently introduced to this CPV susceptible mammalian cell line. Thus, we show evidence that the system could be utilized to study targeting of the CPV capsid proteins.